Angiogenesis is a process by which new blood vessels are formed from preexisting vessels. New blood vessel formation by angiogenesis involves the degradation of extracellular matrix combined with sprouting and migration of endothelial cells from preexisting capillaries. Solid tumors consist of several components, including normal and stromal cells, extracellular matrix, and vasculature. To grow and metastasize, tumors must stimulate the development of new vasculature through angiogenesis. Vascular endothelial growth factor (VEGF) is a potent angiogenic peptide with biologic effects that include regulation of hematopoietic stem cell development, extracellular matrix remodeling, and inflammatory cytokine regeneration. VEGF is both a vascular growth factor and a vascular permeability factor. Its expression can upregulate several proangiogenic and prometastatic molecules. As a central mediator of angiogenesis, VEGF has emerged as an important target for antiangiogenic therapy. In this review, the authors describe the essential characteristics of VEGF and the VEGF family of ligands and their receptors. They also provide an overview of the central role of VEGF in physiologic and pathologic angiogenesis, directly or indirectly. This review sheds light on the importance of VEGF-targeted antiangiogenic therapy based on the monoclonal antibodies against VEGF, small interfering RNA, and therapy directed against VEGF-VEGFR kinase. It also gives a brief overview of the natural products or dietary compounds that could be used as antiangiogenic agents. Therapeutic inhibition of vessel formation could be best suited to preventive strategies aimed at the suppression of angiogenesis in primary tumors in subjects at risk or of micrometastases after surgical removal of primary tumor.
The development of vascular supply is a fundamental requirement for organ development and differentiation during embryogenesis as well as for wound healing and reproductive functions in adults. Angiogenesis is also indicated in the pathogenesis of a variety of disorders: proliferative retinopathies, agerelated macular degeneration, tumors, rheumatoid arthritis, and psoriasis. 1, 2 Vascular endothelial growth factor (VEGF) is the only growth factor proven to be specific and critical as a mitogen for vascular endothelial cells derived from arteries, veins, and lymphatics, but it is devoid of consistent and appreciable mitogenic activity for other cell types. 3 VEGF promotes angiogenesis in tridimensional in vitro models, inducing confluent microvascular endothelial cells to invade collagen gels and form capillary-like structures. 4 Even though VEGF is a potent mitogenic stimulator of endothelial cells, it may also exert effects on cells in a manner unrelated to its angiogenic activity and act as a survival factor. An inverse relationship exists between apoptosis and angiogenesis, 5, 6 several studies have demonstrated the ability of VEGF to function as a survival factor for endothelial cells. Immature blood vessels such as those present in tumors with active angiogenesis are dependent on the presence of VEGF, undergoing regression via apoptosis. 7 VEGF induces vasodilatation in vitro and produces a transient tachycardia, hypotension, and decrease in cardiac output. 8 VEGF is also known as a vascular leakage promoter in guinea pig. It is a potent angiogenic peptide with diverse biological activities that include regulation of embryonic stem cell development, extracellular matrix remodeling, and the local generation of inflammatory cytokines. 9 Several excellent reviews of the VEGF family have been published, and the reader is referred to these for more details.
VEGF-A. Four additional members of the family such as placental growth factor (PIGF), VEGF-B, VEGF-C, and VEGF-D have been identified to date. VEGF is a potent growth factor for blood vessel endothelial cells, showing pleiotropic responses that facilitate migration, proliferation, tube formation, and survival of endothelial cells; thus, VEGF is a common link of inflammation, permeability, and angiogenesis. 13, 14 VEGF-A may exist in 4 isoforms, designated by their expected final amino acid length (VEGF 121 , VEGF 165 , VEGF 189 , VEGF 206 ). These isoforms show similar biological activities but bind with different affinities to heparin and result in different secretion patterns. VEGF 121 is the smallest isoform of VEGF, stabilized by intra-and interdisulfide bonds. VEGF 121 is secreted and completely diffusible, but the largest isoform, VEGF 206 , is almost completely attached to the extracellular matrix. The other 2 show intermediate heparin-binding affinities. VEGF-A exerts its action through 2 recep-tors, VEGFR-1 and VEGFR-2. 13, 14 VEGFR-1 appears to function primarily as a decoy receptor, which decreases the availability of VEGF to VEGFR-2.
PIGF is expressed in the placenta and somewhat less in the heart, lung, and thyroid gland. Placentally expressed PIGF may act as an autocrine growth factor on trophoblasts, which express both PIGF and its receptor (VEGFR-1). Two differentially spliced isoforms of PIGF have been identified. Hypoxia does not induce PIGF synthesis, but the formation of heterodimers would be affected due to hypoxic control over VEGF-A expression. PIGF exerts its action through the receptor VEGFR-1. 13, 15, 16 VEGF-B is largely cell associated and expressed mostly in the heart, skeletal muscle, brain, and kidney. It is often coexpressed with VEGF-A, and heterodimers of A/B have been identified. VEGF-B expression is not regulated by hypoxia. The long half-life of its mRNA (>8 hours) suggests a chronic rather than acute regulation. VEGF-A exerts its action through one receptor, VEGFR-1. 15, [17] [18] [19] VEGF-C, also called VEGF regulated factor or VEGF-2, in the adult is expressed primarily in the heart, placenta, lung, kidney, muscle, ovary, and small intestine. During embryonic development, it is expressed in the cephalic mesenchyme, tail region, allantois, and along the somites. VEGF-C exerts its action through two receptors, VEGFR-2 and VEGFR-3. 20 VEGF-D, also called c-fos induced growth factor, is a VEGF homologue induced by c-fos. It is expressed in adult lung, heart, and small intestine and in the fetal lung and reported to be mildly mitogenic for endothelial cells. VEGF-D and VEGF-C share 23% amino sequence homology. VEGF-D exerts its action through two receptors, VEGFR-1 and VEGFR-2. [21] [22] [23] 
Hypoxia Inducible Factor-1 and VEGF Expression
The mechanism proposed to participate in the regulation of VEGF gene expression, oxygen tension, plays a major role both in in vitro and in vivo systems. 24 VEGF mRNA expression is rapidly and reversibly induced by exposure to low pO 2 in a variety of normal and transformed cultured cell types. 25 Ischemia with occlusion in the artery results in a dramatic increase in VEGF mRNA levels in in vivo experimental models, suggesting the possibility that VEGF may mediate the spontaneous revascularization that follows ischemia. 26 Hypoxia-induced transcription of VEGF mRNA is apparently mediated, at least in part, by the binding of the hypoxia-inducible factor-1 (HIF-1) to an HIF-1 binding site located in the VEGF promoter. 27 HIF-1 has been identified as a mediator of transcriptional response to hypoxia and is a basic, heterodimeric, helixloop-helix protein. 27 It turns out that some mechanisms that lead to elevated VEGF production independently of hypoxia actually short-circuit the normal hypoxia-sensing mechanism that regulates VEGF expression. For example, it was observed that the oncogene v-src can induce expression of HIF-1, thereby short circuiting the HIF-1-dependent hypoxia-sensing mechanism and leading to increased expression of VEGF. 28 In addition to the induction of transcription, hypoxia promotes stabilization of the VEGF mRNA by proteins that bind to sequences located in the 3′ untranslated region of the VEGF mRNA. Recently, one such protein has been identified as the HuR mRNA binding protein. 29 It is clear that additional proteins stabilize the VEGF mRNA, but their identity is still unknown.
VEGF and Physiological Angiogenesis
The proliferation of blood vessels is crucial for a wide variety of physiological processes such as embryonic development, normal growth and differentiation, wound healing, and reproductive functions. During embryogenesis, blood vessels form through 2 distinct processes, vasculogenesis and angiogenesis. Disruptions of both VEGF alleles in mice mimics knockout of VEGFR-2, resulting in almost complete absence of a vasculature. 30 Disruption of even a single VEGF allele in mice leads to embryonic lethality due to severe vascular abnormalities. 31 The most elegant demonstra- tion of the need for exquisite VEGF regulation involves retinal vascularization, which occurs postnatally in rodents. Angiogenic sprouting into the initially avascular and hypoxic rodent retina depends on its VEGF expression. 32 Any perturbation of normal VEGF expression patterns destroys retinal vascularization patterns with dire results for retinal function. 33 Spontaneous angiogenic response of VEGF can be demonstrated using rat thoracic aortic culture. The complexity of the vascular network could be observed in the rat aortic preparations that were cultured in the presence of VEGF (Figure 2) . A complex network of branching microvessels develops from the endothelial cells of the aortic intima, interspersed with fibroblasts as individual cells, thus providing a closer approximation to the angiogenic process as observed in vivo. This process occurs in response to endogenous growth factors such as VEGF in the controlled microenvironment. Angiogenesis is a complex morphogenic process involving the coordinated migration of several cell types including endothelial cells, peritypes, and stromal fibroblasts. Figure 3 demonstrates the impact of VEGF on endothelial cell migration or motility.
VEGF and Receptors

VEGF and Tumor-Specific Angiogenesis
Neovascularization is associated with numerous pathologic processes including cancer, proliferative diabetic retinopathy, and macular degeneration. The pathological angiogenesis necessary for active tumor growth is sustained and persistent with the initial acquisition of the angiogenic phenotype being a common mechanism for the development of a variety of solid and hematopoetic tumor types. 34 Among the angiogenic growth factors, the VEGF family (VEGF-A, VEGF-B, VEGF-C, and VEGF-D) and their corresponding receptor tyrosine kinases (VEGFR-
[FLT-1], VEGFR-2 [FLK-1, KDR], and VEGFR-3 [FLT-4]) play a paramount and indispensable role in regulating the multiple facets of the angiogenic and lymphangiogenic processes (VEGFR-3 [FLT-4])
as well as the induction of vascular permeability and inflammation. 35 The VEGF family has a relatively narrow target cell specificity compared to other pleiotropic angiogenic factors and cytokines, which exert their mitogenic, chemotactic, and thrombogenic effects primarily on endothelial cells implicated in hemangiogenesis (VEGF-A, VEGF-B) and lymphangiogenesis (VEGF-C and VEGF-D). The endotheliotropic activities of the VEGF family are mediated through the receptor tyrosine kinases VEGFR-1/FLT-1, VEGFR-2/KDR, and VEGFR-3/FLT-4, the expression of which is upregulated on vascular endothelial cells during embryonic and tumor angiogenesis. 36 The receptor VEGF-R2/KDR is the principal one through which VEGFs exert their mitogenic, chemotactic, and vascular permeability effects on the host vasculature. 37 Increased expression of VEGFs by tumor-associated vasculature is a hallmark of a variety of human and rodent tumors in vivo and is correlated with tumor growth rate, microvessel density, proliferation, tumor metastatic potential, and poorer patient prognosis in a variety of malignancies. 38 The collective findings show the critical and nonredundant role of VEGF in tumor-associated angiogenesis, mediated by chemotactic activity in monocytes and macrophages, 39 regulating extracellular matrix proteolytic activity 40 and release of tissue factor and nitric oxide in endothelial cells and trophoblasts, 39 and mediating PIGF-induced recruitment and mobiliza-tion of bone marrow-derived endothelial and hematopoetic stem cells in normal and tumor-associated angiogenesis. 41 Much evidence implicates VEGFR-3/ FLT-4 and its ligands, VEGF-C and VEGF-D, in tumor lymphangiogenesis and lymphatic metastasis in multiple solid tumor types. 42 VEGF-A promotes proliferation of endothelial cells and monocytes. It also induces endothelial cell expression of antiapoptotic protein bcl-2 and thus acts as a survival factor for endothelial-like cells. 43 In addition, VEGF can inhibit maturation of dendritic cells. 44 Thus, VEGF-A enriches the pool of cells that can contribute to angiogenesis but also depletes the reservoir of cells involved in host immune response, potentially leading to immunosuppression. In addition to these roles, VEGF-A is a vascular permeability factor, producing leakage of plasma proteins that result in the formation of extravascular fibrin gel, which provides a substrate for endothelial and tumor cell growth. 45
Transcriptional Regulation of VEGF
Nuclear factor-κB (NF-κB) and activated protein (AP-1) have been implicated in the control of VEGF transcription. 46, 47 Inhibition of NF-κB activity reduced VEGF expression as well as tumorigenicity and angiogenesis in several cancer models. 48, 49 AP-1 has been shown to act synergistically with NF-κB to promote IL-8 transcription 50 and to play a role in IL-8 expression in response to hypoxia. 51 AP-1 has also been shown to play a positive role in the induction of VEGF expression by hypoxia, transforming growth factor-β, and acidosis. 52 Several factors that can potentiate VEGF production include fibroblast growth factor 4, plateletderived growth factor, tumor necrosis factor-α, transforming growth factor-β, keratinocyte growth factor, insulin-like growth factor, interleukin-1β, and IL-6. 53 Moreover, all these cytokines are regulated by the transcription factors NF-κB and AP-1 directly or indirectly.
VEGF-Mediated Antiangiogenic Therapy
Direct evidence of the role of VEGF in tumorigenesis was provided by studies with monoclonal antibodies against VEGF. Inhibition of growth of a wide variety of human tumor cell lines (carcinomas, sarcomas, and gliomas) in mice by antihuman VEGF monoclonal antibodies correlated with nearly complete suppression of tumor-associated angiogenesis. 54 Several inhibitors of angiogenesis are currently in clinical development for the treatment of cancer. The agents include antibodies such as neutralizing anti-VEGF antibody, an antibody against VEGF receptors. 55 Many of these agents block angiogenesis either by blocking the VEGF receptor or by neutralizing VEGF itself. There are indirect angiogenic inhibitors such as HER-2 neutraliz-ing antibody (trastuzumab), which indirectly inhibits angiogenesis because its target (HER-2) stimulates VEGF expression. 55 The in vivo regulation of a VEGF gene by RNA interference has been blocked by the ability of tumor cells to secrete high levels of VEGF, which could diminish or prevent the triggering of therapeutic resistance of tumor cells. It has been reported that small interfering RNA-mediated inhibition of VEGF severely limited the tumor resistance to antiangiogenic thrombospondin-1 and slowed tumor vascularization and growth. 56 Antiangiogenesis therapies directed against the VEGF-VEGF-R kinase axes through a variety of approaches have been a promising and well-validated therapeutic approach and are under active evaluation for their safety and efficacy in multiple clinical trials. In addition, several orally active small molecule inhibitors of specific VEGFR-kinases, including PTK-787 (vatalinib), PKC-412 (midstaurin), ZD-6474, SU-11248, and CP-547/632, are currently under clinical evaluation for the development of antiangiogenic molecules. 38 The pharmacological, pharmacokinetic, and tolerability profile of these agents in preclinical studies is compatible with chronic administration against a variety of solid tumors.
Effect of Natural Products on VEGF-Mediated Angiogenesis
A variety of studies have suggested the inhibitory role of natural product and dietary compounds on tumorspecific angiogenesis. Our laboratory has reported the effect of Tinospora cordifolia (Willd.) Miers (Menispermaceae) on the inhibition of VEGF production and tumor-specific angiogenesis in mice. 57 Several other studies of the impact of natural products on tumor-specific angiogenesis are being conducted in our laboratory. Resveratrol, a polyphenolic compound found in grapes and other fruits, has been reported to inhibit VEGF-induced angiogenic effects in human umbilical vein endothelial cells. 58 The inhibitory effect of indole-3-carbinol, a major indole metabolite in cruciferous vegetables, on cell proliferation and in vitro markers of angiogenesis in phorbol myristate acetate-stimulated endothelial cells has been reported. 59 Capsaicin, a natural product present in Capsicum species, inhibits VEGF expression and related angiogenesis in in vitro as well as in vivo models. 60 It was found that sanguinarine, a benzophenanthridine alkaloid derived from the root of Sanguinaria canadensis L. (Papaveraceae), strongly suppressed basal and VEGF-induced Akt phosphorylation, which inhibits angiogenesis. 61 Ellagic acid, another natural polyphenolic compound found in fruits and nuts, inhibits VEGF-induced phosphorylation of VEGFR-2 and angiogenesis. 62 The antiangiogenic potency of vitamin E, catechin, and green tea catechins has also been reported previously. 63, 64 These agents appear to target common mechanisms of tumor angiogenesis that may permit identification of critical targets for antiangiogenic therapy and antiangiogenic chemoprevention. Thus, compounds that inhibit the effects of VEGF have the potential to provide a novel, effective, and well-tolerated therapy for solid tumors. These agents may also provide a new therapeutic approach for the treatment of other diseases in which angiogenesis plays an important role.
Conclusion
This review discusses the multiple roles of VEGF in tumor-specific angiogenesis. VEGF, in its function as a master regulator of the angiogenic switch, promotes angiogenesis through multiple and complementary mechanisms. Not only does it promote the recruitment and proliferation of endothelial cells and their precursors within the tumor, but it also furnishes nearby host vessels for the necessary plasticity to support angiogenesis in developing tumors.
